This is the first time a Canadian company has legally cultivated and harvested psychedelic mushrooms since the 1970s.
This collaboration will study a full spectrum of pharmacological effects of several synthetic tryptamine compounds.
This technology may help ease some of the concerns surrounding psychedelic therapy.
The scope and validity of the patent will depend on how x-ray diffraction data is interpreted.
Nasal spray formulations like this could offer precision dosing of a spectrum of psychedelic mushroom compounds to consumers.
German entrepreneur and investor Christian Angermayer creates Atai Life Sciences and raises $25 million to study the therapeutic effects of psychedelic drugs on depression and other mental illnesses.
Sandoz Pharmaceutical starts manufacturing psilocybin in pill form.
Sandoz Laboratories markets LSD under the trade name Delysid.